4-(diphenylmethoxy)benzaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(diphenylmethoxy)benzaldehyde
• 英文别名: 4-benzhydryloxybenzaldehyde
• 化学式: C₂₀H₁₆O₂
• 分子量: 288.346
• InChiKey: COQHVRMZOSMXJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(diphenylmethoxy)benzaldehyde 在 盐酸 、 potassium carbonate 作用下， 以 二氯甲烷 、 氯仿 、 乙酸乙酯 为溶剂， 反应 147.0h， 生成 {[4-(diphenylmethoxy)phenyl]methyl}[(4-fluorophenyl)methyl]{[4-(trifluoromethyl)-1H-imidazol-2-yl]methyl}amine
  参考文献：
  名称：

  Inhibitors of matrix metalloproteinases

  摘要：

  通式（I）化合物、其盐或溶剂化合物以及含有这些化合物的药物组合物：其中Z为N或CH，或Z（R1）部分被共价键替换，m和n为0、1、2或3；HET为杂环芳基；X为CF3、卤素、CO-杂环烷基、COOR3或CONHR3；R1为H、（CH2）o-芳基、（CH2）p-杂环芳基、（CH2）q-联苯基；C（O）—R5；S（O）2—R6；R2为H、芳基、杂环芳基、Y—（CH2）r-芳基、Y—（CH2）s-杂环芳基，其中上述取代基中的一些可能被取代；Y为O或S；不包括HET为1,3-噻唑、X为COOH、R1为4-氟苯基和R2为苄氧基的化合物。该发明还涉及使用通式（I）化合物、其盐或溶剂化合物用于预防或治疗MMPs激活参与病理机制的疾病。在这方面，上述排除的化合物的使用也是创新的。

  公开号：

  US09487462B2
• 作为产物：
  描述：

  对羟基苯甲醛 、 二苯基溴甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以61%的产率得到4-(diphenylmethoxy)benzaldehyde
  参考文献：
  名称：

  Inhibitors of matrix metalloproteinases

  摘要：

  通式（I）化合物、其盐或溶剂化合物以及含有这些化合物的药物组合物：其中Z为N或CH，或Z（R1）部分被共价键替换，m和n为0、1、2或3；HET为杂环芳基；X为CF3、卤素、CO-杂环烷基、COOR3或CONHR3；R1为H、（CH2）o-芳基、（CH2）p-杂环芳基、（CH2）q-联苯基；C（O）—R5；S（O）2—R6；R2为H、芳基、杂环芳基、Y—（CH2）r-芳基、Y—（CH2）s-杂环芳基，其中上述取代基中的一些可能被取代；Y为O或S；不包括HET为1,3-噻唑、X为COOH、R1为4-氟苯基和R2为苄氧基的化合物。该发明还涉及使用通式（I）化合物、其盐或溶剂化合物用于预防或治疗MMPs激活参与病理机制的疾病。在这方面，上述排除的化合物的使用也是创新的。

  公开号：

  US09487462B2

文献信息

• Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
  申请人：CoCensys, Inc.

  公开号：US20020061886A1

  公开（公告）日：2002-05-23

  This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R 1 , R 21 , R 22 and R 23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R 22 and R 23 , together with the N, form a heterocycle; A 1 and A 2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR 24 , CR 25 R 26 , C(O), NR 24 C(O), C(O)NR 24 , SO, SO 2 or a covalent bond; where R 24 , R 25 and R 26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.

  这项发明涉及由式I表示的含有碳环和杂环取代的半卡巴松和硫代半卡巴松： 1 或其药学上可接受的盐或前药，其中： Y为氧或硫；R 1 ，R 21 ，R 22 和R 23 独立地为氢，烷基，环烷基，烯基，炔基，卤代烷基，芳基，氨基烷基，羟基烷基，烷氧基烷基或羧基烷基；或R 22 和R 23 ，与N一起形成一个杂环；A 1 和A 2 独立地为芳基，杂芳基，饱和或部分不饱和的碳环或饱和或部分不饱和的杂环，其中任何一个可选择地被取代；X为O、S、NR 24 、CR 25 R 26 、C(O)、NR 24 C(O)、C(O)NR 24 、SO、SO 2 或共价键；其中R 24 ，R 25 和R 26 独立地为氢，烷基，环烷基，烯基，炔基，卤代烷基，芳基，氨基烷基，羟基烷基，烷氧基烷基或羧基烷基。该发明还涉及利用含有碳环和杂环取代的半卡巴松和硫代半卡巴松治疗全脑和局部缺血后的神经损伤，治疗或预防神经退行性疾病如肌萎缩侧索硬化症（ALS），治疗和预防耳神经毒性和涉及谷氨酸毒性的眼病，以及治疗、预防或改善疼痛，作为抗癫痫药，作为抗躁狂抑郁药，作为局部麻醉药，作为抗心律失常药，以及治疗或预防糖尿病性神经病变和尿失禁。
• NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Ferdinandy Péter

  公开号：US20130303572A1

  公开（公告）日：2013-11-14

  Compounds of general formula (I), salts or solvates thereof and pharmaceutical compositions containing same: wherein Z is N or CH or the Z(R1) part is replaced with a covalent bond, m and n is 0, 1, 2 or 3; HET is heteroaryl; X is CF 3 , halogen, CO-heterocyclyl, COOR3 or CONHR3; R1 is H, (CH 2 ) o -aryl, (CH 2 ) p -heteroaryl, (CH 2 ) q -biphenyl; C(O)—R5; S(O) 2 —R6; R2 is H, aryl, heteroaryl, Y—(CH 2 ) r -aryl, Y—(CH 2 ) s -heteroaryl, where some of the above substituents may be substituted; Y is O or S; with the exclusion of the compound where HET is 1,3-thiazol, X is COOH, R1 is 4-fluorophenyl and R2 is benzyloxy. The invention also relates to the use of a compound of general formula (I), salts or solvates thereof for the use in the prevention or treatment of diseases where the activation of MMPs is involved in the pathomechanism. In this aspect the use of the above excluded compound is also inventive.

  通式（I）的化合物，其盐或溶剂合物以及含有它们的药物组合物：其中Z为N或CH，或者Z（R1）部分被共价键替换，m和n为0、1、2或3；HET为杂环芳基；X为CF3、卤素、CO-杂环烷基、COOR3或CONHR3；R1为H、（CH2）o-芳基、（ ）p-杂环芳基、（ ）q-联苯基；C（O）-R5；S（O）2-R6；R2为H、芳基、杂环芳基、Y-（ ）r-芳基、Y-（ ）s-杂环芳基，其中一些上述取代基可能被取代；Y为O或S；不包括HET为1,3-噻唑，X为COOH，R1为4-氟苯基和R2为苄氧基的化合物。本发明还涉及使用通式（I）的化合物、其盐或溶剂合物用于预防或治疗涉及MMPs激活的病理机制的疾病。在这方面，上述被排除的化合物的使用也是创新的。
• Arylalkoxyphenyl-allylic alcohols as agents for the treatment of hypersensitive ailments
  申请人：USV PHARMACEUTICAL CORPORATION

  公开号：EP0189142A2

  公开（公告）日：1986-07-30

  The present invention is concerned with the therapeutic composition comprising as an active ingredient a compound of the formula: and salts thereof, wherein a = 1, 2 or 3; each b = 1 or 2 and is the same value as the other; Ar is phenyl or naphthyl containing one or two substituents selected from the group consisting of hydrogen, alkoxy, aryloxy, hydroxy, hydroxyalkyl, alkyl, aryl, halo, CF3, carboxy, carbalkoxy, carboxyalkoxy, carbalkoxyalkoxy, lower acyl, nitrilo, amino, nitro, mercapto or alkylthio; Ar1 is phenyl, naphthyl, or a nitrogen, oxygen or sulfur heterocyclic ring; each R1 is independently hydrogen, alkyl, carboxy, carbalkoxy, alkylenecarboxy, arylenecarboxy, alkylenecarbalkoxy, alkanoyl, formyl, nitrilo, amino, aminoalkylene, alkylamino, carboxamide, halo, trihalomethyl, hydroxy, alkoxy, aralkyloxy, aryloxy, nitro, sulfamyl, mercapto or alkylthio; each R is H or alkyl; Z is an alkylene chain containing up to 10 carbon atoms in the principal chain and up to a total of 12 carbon atoms and from 0 to 2 double bonds and Z when taken together with the carbon atom of (CR=CR) to which it is attached forms a cycloalkylidene ring; each R2 is a substituent attached to one of the carbon atoms of Z selected from the group consisting of OR4, SR4, NiH4)2, CHO and COR5; each R3 is H, cycloalkyl, aralkyl, aryl, lower dialkylamino, morpholino, piperazino, piperidino or CF3; each R4 is H, alkyl, benzoyl, lower alkanoyl, aryl or aralkyl; R5 is OR6 or N(R4)2; R6 is H, alkyl, aryl, or aralkyl; n = 1 or 2; n' = 1 or 2; n" = 1 or 2; n"' = 1 or 2; alkylene of up to 2 carbon atoms in the principal chain and up to a total of 4 carbon atoms, -C(R7) = C(R7)-, -C≡C-, m = 0 or 1; m' = 0, 1, or 2; and R7 is H, CH3 or phenyl; wherein the group(s) designated [(R1)n-Ar1-(X)bla is (are) attached directly to Ar. In addition, the present invention relates to the method of using these compounds as lipoxygenase inhibitors possessing anti-inflammatory and anti-allergic responses.

  本发明涉及治疗组合物，其活性成分包括式化合物 及其盐类、 其中a＝1、2或3；每个b＝1或2，且与另一个值相同； Ar 是苯基或萘基，含有一个或两个取代基，这些取代基选自氢、烷氧基、芳氧基、羟基、羟烷基、烷基、芳基、卤素、CF3、羧基、羧基烷氧基、羧基烷氧基、羧基烷氧基、低级酰基、硝基、氨基、硝基、巯基或烷硫基组成的组； Ar1 是苯基、萘基或氮、氧或硫杂环； 每个 R1 独立地是氢、烷基、羧基、碳烷氧基、烷烯羧基、芳烯羧基、烷烯碳烷氧基、烷酰基、甲酰基、硝酰基、氨基、氨基烷基、烷基氨基、甲酰胺、卤素、三卤甲基、羟基、烷氧基、芳烷氧基、芳基氧基、硝基、氨基磺酰基、巯基或烷硫基； 每个 R 均为 H 或烷基； Z 是亚烷基链，在主链中最多含有 10 个碳原子，总共最多含有 12 个碳原子和 0 至 2 个双键，Z 与所连接的 (CR=CR) 的碳原子一起形成一个亚环烷基环； 每个 R2 是与 Z 的一个碳原子相连的取代基，选自 OR4、SR4、NiH4)2、CHO 和 COR5 所组成的组； 每个 R3 是 H、环烷基、芳烷基、芳基、低级二烷基氨基、吗啉基、哌嗪基、哌啶基或 ； 每个 R4 是 H、烷基、苯甲酰基、低级烷酰基、芳基或芳烷基；R5 是 OR6 或 N(R4)2； R6 是 H、烷基、芳基或芳烷基； n = 1 或 2； n' = 1 或 2 n" = 1 或 2 n"' = 1 或 2； 主链上最多 2 个碳原子且总共最多 4 个碳原子的亚烷基，-C(R7) = C(R7)-，-C≡C-、 m = 0 或 1； m' = 0、1 或 2；以及 R7 是 H、CH3 或苯基； 其中指定为[(R1)n-Ar1-(X)bla]的基团直接连接到 Ar。 此外，本发明还涉及将这些化合物用作具有抗炎和抗过敏反应的脂氧合酶抑制剂的方法。
• The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers
  申请人：Euro-Celtique S.A.

  公开号：EP1568690A1

  公开（公告）日：2005-08-31

  This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R1, R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R22 and R23, together with the N, form a heterocycle; A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where R24, R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention is also directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyiotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.

  本发明涉及式(I)代表的碳环和杂环取代的半咔唑酮和硫代咔唑酮，或其药学上可接受的盐或原药，其中：Y是氧或硫；R1、R21、R22和R23独立地是氢、烷基、环烷基、烯基、炔基、卤代烷基、芳基、氨基烷基、羟基烷基、烷氧基烷基或羧基烷基；或R22和R23与N一起形成杂环；A1和A2独立地是芳基、杂芳基、饱和或部分不饱和碳环或饱和或部分不饱和杂环，其中任何一个都被任选取代；X是一个或O、S、NR24、CR25R26、C(O)、NR24C(O)、C(O)NR24、SO、SO2或共价键；其中R24、R25和R26独立地是氢、烷基、环烷基、烯基、炔基、卤代烷基、芳基、氨基烷基、羟基烷基、烷氧基烷基或羧基烷基。本发明还涉及碳环和杂环取代的半咔唑酮和硫代咔唑酮用于治疗全局性和局灶性缺血后的神经元损伤，治疗或预防神经退行性疾病，如肌萎缩性脊髓侧索硬化症（ALS）、用于治疗和预防耳神经毒性和涉及谷氨酸毒性的眼部疾病，用于治疗、预防或改善疼痛，用作抗惊厥药、抗躁狂抑制剂、局部麻醉剂、抗心律失常药，以及用于治疗或预防糖尿病神经病变和尿失禁。
• CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF
  申请人：CoCensys, Inc.

  公开号：EP0986540A1

  公开（公告）日：2000-03-22